Published in Gastroenterology on January 01, 2002
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology (2003) 1.00
Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol (2004) 0.91
Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B. Hepatol Int (2008) 0.82
Prevalence and Immunization Status of Hepatitis B Virus in the HIV Cohort in Fife, Scotland. J Clin Med Res (2010) 0.80
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine. BMC Infect Dis (2004) 0.79
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology (2001) 4.81
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology (2003) 2.80
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
New insight in the pathobiology of hepatitis B virus infection. Gut (2012) 2.54
Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust (2009) 2.42
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int (2010) 2.12
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology (2002) 2.01
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81
Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. J Infect Dis (2005) 1.81
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
HBV drug resistance: mechanisms, detection and interpretation. J Hepatol (2006) 1.71
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis (2005) 1.66
Lamivudine resistant occult HBV: implications for public health? J Hepatol (2003) 1.64
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology (2004) 1.56
Gastrointestinal histoplasmosis in the acquired immunodeficiency syndrome: report of 18 cases and literature review. Diagn Microbiol Infect Dis (2006) 1.55
Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol (2007) 1.54
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS (2006) 1.52
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut (2012) 1.47
Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol (2002) 1.45
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 1.38
Management of treatment failure in chronic hepatitis B. J Hepatol (2012) 1.33
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31
96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol (2007) 1.28
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology (2002) 1.22
Hepatitis C in a Los Angeles public hepatitis clinic: demographic and biochemical differences associated with race-ethnicity. Clin Gastroenterol Hepatol (2004) 1.22
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology (2003) 1.22
Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis (2012) 1.19
SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res (2006) 1.16
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS (2003) 1.15
Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother (2006) 1.14
The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol (2011) 1.13
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother (2007) 1.13
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol (2013) 1.10
Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis (2007) 1.09
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol (2003) 1.08
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology (2009) 1.07
Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol (2003) 1.05
Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother (2002) 1.05
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int (2013) 1.04
More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol (2006) 1.03
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99
Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther (2009) 0.98
Increased prevalence of HBV envelope mutants in Taiwan: an emerging public health risk or a false alarm? Gastroenterology (2012) 0.98
HBV genotyping and analysis for unique mutations. Methods Mol Med (2004) 0.97
An update on HDV: virology, pathogenesis and treatment. Antivir Ther (2013) 0.97
Antiviral resistance and direct-acting antiviral agents for HCV. Antivir Ther (2012) 0.97
The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int (2009) 0.95
Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. J Virol (2008) 0.95
Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ (2009) 0.95
Molecular and clinical characteristics of hepatitis B virus in Korea. J Med Virol (2010) 0.95
Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother (2002) 0.94
New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology (2003) 0.94
Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr (2007) 0.93
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis (2013) 0.93
Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev (2007) 0.92
Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease. J Virol (2011) 0.92
Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol (2007) 0.90
Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med (2004) 0.90
Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology (2012) 0.89
Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol (2004) 0.88
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS (2007) 0.88
Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody. Virology (2011) 0.87
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J Clin Virol (2003) 0.87
The natural history and the staging of chronic hepatitis B: time for reevaluation of the virus-host relationship based on molecular virology and immunopathogenesis considerations? Gastroenterology (2007) 0.87
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol (2010) 0.87
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology (2008) 0.86
Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol (2010) 0.86
Hepatitis B precore protein: pathogenic potential and therapeutic promise. Yonsei Med J (2012) 0.86
Changing landscape of antiviral resistance management in chronic hepatitis B. J Gastroenterol Hepatol (2008) 0.86
Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses. J Med Virol (2010) 0.86
The new front-line in hepatitis B/D research: identification and blocking of a functional receptor. Hepatology (2013) 0.86
Hepatitis B virus: pathogenesis, viral intermediates, and viral replication. Clin Liver Dis (2004) 0.85
Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol (2006) 0.85
Highly active antiretroviral therapy-induced liver injury. Curr Drug Saf (2008) 0.84